274 results about "Brain glioma" patented technology

The invention discloses a dual target liposome and a preparation method and application thereof. The target liposome provided by the invention consists of liposome and modifiers on the surface of the liposome, wherein the modifiers on the surface of the liposome comprise p-aminophenyl-alpha-D-manno-pyranoside and transferrin. The invention also discloses a medicament-loaded liposome, which is obtained by wrapping daunorubicin by using the target liposome. The obtained target liposome has good capability of crossing the blood brain barrier, targets brain glioma, and can be used as a medicament carrier. The medicament-loaded liposome can target the medicament to a brain glioma site after crossing the blood brain barrier so as to greatly increase the concentration of the medicament at a tumor site and improve the effect of chemotherapy. The target liposome provides a new measure for brain glioma chemotherapy, contributes to the research of non-invasive therapy of the brain glioma, and has important theoretical meaning and clinical meaning.

The invention provides a human brain glioma cell line and an establishing method and application thereof. The human brain glioma cell line is preserved in China Center for Typical Culture Collection with an accession number of CCTCC No. C201115. The human brain glioma cell line is established by subjecting brain glioma cells originated from a clinic specimen to primary culture and subculture, can be directly used for in vitro drug screening or generation of human brain glioma in mammals and is used for establishing a human brain glioma animal model and screening candidate drugs used for treating human brain glioma. The human brain glioma cell line has stable properties, can realize stable multiple passages and maintain stable properties even after in vitro passage to the 50th generation; pathogenesis of human brain glioma, drug susceptibility, transitivity and other related characteristics can be analyzed in vitro and in vivo, so two correlated in-vitro and in-vivo anti-brain glioma drug screening platforms can be established, and novel experimental materials closer to clinic oncobiological characteristics are provided for research on human brain glioma.

The invention belongs to the field of pharmacy and relates to a D-configuration polypeptide and a gene delivery system of the D-configuration polypeptide and particularly relates to the D-configuration polypeptide which has high combining activity with neuropilin NRP-1 and has the brain tumor targeting and tumor tissue penetrating capabilities. The D-configuration polypeptide provided by the invention can mediate a nano delivery system to deliver drugs to tumors in a targeted manner for realizing targeted treatment of brain in-situ glioma. In vivo and in vitro experiments show that the genetic vector modified by the D-configuration polypeptide can remarkably improve the gene transfection efficiency. The genetic vector entrapping the therapeutic gene pORF-hTRAIL can remarkably prolong the lifetime of a nude mouse of brain glioma in-situ mode.

The invention discloses application and a preparation method of tripterine. The tripterine can be used for preparing the drug for treating brain glioma. The preparation method of the tripterine comprises the following steps: (1) mixing and crushing the above-ground vine part and underground root part of Tripterygium wilfordii, carrying out reflux extraction with ethanol, filtering and concentrating at reduced pressure; (2) ultrasonically mixing and suspending the concentrated ethanol extract with ethanol-water, standing still and pouring out supernatant; (3) separating the supernatant with adsorbent resin, carrying out sequential gradient eluting with ethanol-water, and collecting eluate; (4) concentrating the eluate at reduced pressure, purifying by silica gel column chromatography, recovering solvent and drying to obtain red powdery extract; and (5) dissolving the extract with hot ethanol to obtain saturated or unsaturated solution, standing to precipitate red crystals and drying. Compared with the prior art, the method has the advantages of high raw material utilization rate, environmental friendliness, simpleness and low cost and is suitable for industrial production; in addition the purity of the prepared product is high.

The invention discloses a manganese oxide nanoparticle contrast agent for specifically targeting brain glioma. The manganese oxide nanoparticle contrast agent is prepared by the following steps: dispersing an inorganic manganese compound and sodium oleate into a mixed liquor of ethanol, water and normal hexane, and reacting at 50-70 DEG C to prepare precursor manganese oleate; dissolving the manganese oleate precursor into 1-octadecene, and stirring at 80-100 DEG C under protection of nitrogen; heating to 280-320 DEG C under protection of nitrogen, and refluxing to obtain oleic acid-encapsulated manganese oxide nanoparticles; dispersing the oleic acid-encapsulated manganese oxide nanoparticles into methylbenzene; adding a little of acetic acid, carrying out ultrasonic treatment, and adding a silylating reagent to react, so as to obtain silylanized manganese oxide nanoparticles; dispersing the manganese oxide nanoparticles into deionized water, and bonding specifically targeted molecules of the brain glioma, so as to obtain the manganese oxide nanoparticles for specifically targeting the brain glioma. The manganese oxide nanoparticles disclosed by the invention can be used as a novel nuclear magnetic resonance imaging (MRI) contrast agent for early diagnosis and boundary definition of the brain glioma.

The invention provides a method and device for grading evaluation of brain glioma, wherein the method comprises the following steps: obtaining a pathological slice image of the brain glioma of a target patient; Based on the neural network technology, the glioma pathological slice image is recognized, and the cell density, the number of atypical cells, the vascular wall hyperplasia area and the total necrotic tissue area corresponding to the glioma pathological slice image of the target patient are obtained respectively; and generating corresponding pathological condition labeling information of a target patient, and grading the pathological condition labeling information by a pre-trained support vector machine pathological grading model to obtain a grading evaluation result. The inventiongreatly improves the identification accuracy rate and the grading evaluation efficiency, reduces the workload of grading evaluation for the CT tomographic images of patients, and brings convenience tothe work of grading diagnosis.

The invention discloses a multi-modal MR image brain tumor segmentation method based on deep learning and multi-guidance, belongs to the field of image processing, and solves three problems in a multi-modal MRI brain glioma segmentation process: (1) the problem of inaccurate segmentation caused by unclear brain glioma boundary; (2) some discrete wrong segmentation points appear in a segmentation result due to uneven brightness distribution of the multi-mode MRI; and (3) the problem of carrying out feature fusion on various kinds of guide information in a brain glioma MRI segmentation network.Feature fusion is carried out on an overall brain glioma segmentation result and a brain glioma edge prediction result through a proposed fusion mechanism, so that multi-mode MRI brain glioma segmentation under multi-feature map guidance and fusion is realized. According to the deep segmentation network, high-accuracy segmentation is realized with less parameter quantity, so that the method is convenient to embed into edge equipment to assist doctors in diagnosing and analyzing brain glioma.

The method is applied to the technical field of artificial intelligence, relates to the technical field of blockchain, and discloses a brain tumor image segmentation method, device and equipment basedon deep learning, and a medium. The method includes, in part, the following steps: obtaining a multi-mode brain nuclear magnetic resonance image; preprocessing the brain nuclear magnetic resonance image, so as to obtain a target image with the skull part being removed; and finally, inputting the target image into a preset brain tumor segmentation model, so as to obtain a brain tumor image segmentation result, wherein the preset brain glioma segmentation model is a deep learning model obtained by performing cross validation training according to an adaptive segmentation framework and a brain nuclear magnetic resonance image without a skull part, and the adaptive segmentation framework comprises a plurality of different types of U-Net models and U-Net integrated models. According to the invention, the optimal network structure for prediction in the plurality of models can be automatically selected according to the result of cross validation, and the segmentation performance of the preset brain tumor segmentation model is improved, so the accuracy of brain tumor image segmentation is improved.

The invention a bionic acid-sensitive nano drug as well as a preparation method and an application method thereof. The bionic acid-sensitive nano drug comprises an inner core and an outer shell, wherein the outer shell comprises a targeted modified red blood cell membrane. The bionic acid-sensitive nano drug has immune-free natural biological characteristics, and can greatly prolong in-vivo circulating time of the nano drug; and the inner core comprises a carrier with a sensitive bond on a side chain, and can effectively release the drug to achieve the purpose of targeted treatment of tumors.The preparation method for the bionic acid-sensitive nano drug is simple, is suitable for large-scale production, is suitable for preparing the targeted treatment drug, is preferably suitable for preparing the tumor targeted treatment drug, and is especially suitable for preparing a brain glioma targeted treatment drug, and effectively solves the key problems that the existing nano-drug is short in in-vivo circulating time, has difficulty in crossing BBB, is low intake amount by tumor cells, is low in release at a focus, and the like.

The invention is a method for brain glioma computer aided diagnosing system based on data excavating. The invention carries on attributes digitized process to data in the case bank at first by using the information in the case bank of the alioma sufferer, and creates the fuzzy membership relation to the digitized relation. Then the invention uses the fuzzy principle extraction method of the fuzzy maximal and minimal nerve network. The principle of diagnosis for excavating and discovering the alioma malignancy degree, the system is created according to the principle. The system can acquire the malignancy degree of any new case, acquires a high accuracy.

The invention provides a mass spectrometry model used for detecting glioma serum characteristic protein and a preparation method thereof. The method uses a plurality of different characteristic protein combinations of glioma patients and normal people and detects the glioma serum, adopts a method combining the traditional statistics and the modern biological informatics to process data, measures the protein combination spectrogram of serum samples of glioma patients and normal people by a mass spectrograph, and screens out the tumor markers of 12 corresponding glioma characteristic proteins, thus preparing the mass spectrometry model used for detecting glioma serum characteristic protein and providing foundation and resource for finding newer and more ideal tumor markers.

The invention relates to a gadolinium oxide targeted magnetic resonance contrast agent, which is polyethylene glycolized Gd2O3 modified by folic acid, expressed as FA-PEG-Gd2O3 and shaped like near-spheres under a transmission electron microscope. A preparation method comprises the following steps: preparing gadolinium oxide nano-particles coated by oleic acid through a high-temperature reduction method, treating gadolinium acetylacetonate in an organic phase to ensure homogeneity and high crystallinity, and performing ligand exchange with silane carboxylic acid to obtain the gadolinium oxide nano-particles with high water solubility. Then, a large number of carboxyl groups of silane are further coupled with NH2-PEG-COOH and NH2-PEG-FA to obtain the gadolinium oxide targeted magnetic resonance contrast agent which is used for early diagnosis of brain glioma.

The invention relates to the field of gene engineering, and discloses a recombinant herpes simplex virus as well as a preparation method and application of the recombinant herpes simplex virus. Particularly, the recombinant herpes simplex virus comprises a carrier and an exogenous nucleotide sequence, wherein the carrier is a herpes simplex virus of at least one of a gene lacking codes ICP34.5 andICP47 and a selected gene lacking the codes ICP6, TK and UNG; an insertion site of the exogenous nucleotide sequence is at least one of positions of the genes lacking the codes ICP34.5, ICP47, ICP6,TK and UNG on the carrier; the exogenous nucleotide sequence comprises a nucleotide sequence capable of reducing the expression level of the TSPO gene. The invention also discloses application of reduction of the expression level of the TSPO gene in the brain glioma cell in preparation of medicine for treating the brain glioma. The recombinant herpes simplex virus disclosed by the invention has agood anti-brain glioma effect.

The invention relates to a preparation method of a composite for treating brain glioma. The method includes the following steps that firstly, heparin serves as a carrier to carry cRGD tumor targetingpeptide, the heparin is connected with adriamycin amycin through a chemical acid-sensitive hydrazone bond, and adriamycin amycin nano-medicine is prepared; then under catalysis of EDC/NHS, carboxyl onthe adriamycin amycin nano-medicine is coupled with amino on the surface of exosome together, and therefore nano-particles of the adriamycin amycin nano-medicine are densely distributed on the surfaces of vesicae of the exosome. The composite for treating brain glioma prepared with the method can be targeted on tumors and pass through blood brain barriers and further has the advantage of being high in medicine loading capacity.

The invention provides application of sinomenine to preparation of a medicament for treating human brain glioma. As proved by experiments, the sinomenine has a function of restraining human-derived glioma U87MG and SF767 cell strains, and the function is improved along with the increase of dose and time. Moreover, the sinomenine can induce the increase of autophagosomes, increase the quantity of autophagic vesicles, prompt the expression increase of human glioma cells LC3B-II, induce autophagic death of human glioma cells, and restrain the growth of U87MG cell xenograft tumors. The sinomenine is a novel and effective glioma-resisting medicament with a great potential, and can be used for preparing a human brain glioma medicament; by adopting the sinomenine, a new way is created for medical treatment of human brain glioma, and the medical application of the sinomenine is expanded.

The invention discloses a method for detecting the methylation of a brain glioma MGMT promoter gene. The specific steps comprise: extracting the DNA from the brain glioma tissue of a patient by using a tissue DNA extraction kit; carrying out sulfurization treatment on the extracted DNA by using a methylation modification kit; carrying out touchdown PCR on the DNA site template being subjected to the sulfurization modification by using methylation primers represented by SEQ ID NO 1 and SEQ ID 2; diluting the site template 1000 times by using the product obtained through PCR amplification with the methylation primers represented by SEQ ID NO 1 and SEQ ID 2, and carrying out common PCR amplification with primers represented by SEQ ID NO 3 and SEQ ID 4; carrying out 1% agarose gel electrophoresis on the product obtained through the common PCR amplification with the primers represented by SEQ ID NO 3 and SEQ ID 4; recovering the target strip from the 1% agarose gel electrophoresis strips by using an agarose gel recovery kit; carrying out linking transformation on the PCR product and a T carrier, and carrying out blue-white screening; screening recon through bacterial colony PCR; sequencing the positive clones; and analyzing the sequencing results by using biq-analyzer software. The method of the present invention has advantages of high detection accuracy, convenient use, and the like.

The invention discloses a dual-targeted liposome, and a preparation method and application thereof. The dual-targeted liposome comprises liposome and ligands for surface modification, wherein the ligands are folic acid and transferrin. The invention also provides a preparation method of the dual-targeted liposome, and application of the dual-targeted liposome in preparation of a drug for treating brain glioma. The dual-targeted liposome disclosed by the invention is modified by two ligands, plays the dual-targeted role, and can help doxorubicin hydrochloride span a blood brain barrier; and transferrin and folic acid of the dual-targeted liposome disclosed by the invention are safe and nontoxic, are inherent ingredients in the body, and are high in security and good in biocompatibility.

The invention belongs to the field of medicines, and particularly relates to a medicine composition and application thereof in preparation of medicines for treating brain glioma. The medicine composition is prepared from the following medicinal active ingredients: elemene and pomalidomide in an optimal proportion of (0.003-100):1, and a further optimal proportion of (0.01-50):1. Massive pharmacological experiments prove that elemene and pomalidomide have remarkable synthetic effects in the field of brain glioma treatment, and can be used for remarkably reducing the tumor size and weight and prolonging the surviving period. The medicine composition has the advantages of exact curative effect and small toxic and side effects when being used for treating brain glioma, and has good medical application prospects.

The invention belongs to the field of biological medicine, relates to a novel brain glioma treatment target, in particular to ribonuclease 4 protein serving as the brain glioma treatment target, further relates to siRNA, shRNA and a neutralizing antibody of the ribonuclease 4 and includes application of the drug prepared from the siRNA, shRNA and the neutralizing antibody and serving as the target to inhibition of growth of brain glioma.The invention discloses application of RNASE4 serving as the drug target to brain glioma inhibition drugs, and the RNASE4 is the ribonuclease 4 and has the amino acid sequence as shown in SEQ ID NO: 1.